Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16397785 | 1.00 | GPR35 (0.46) | GPR35CYP1A2TDP1TSHRL3MBTL1 | |
| SCHEMBL3535123 | 0.87 | GPR35 (0.54) | GPR35CYP1A2TDP1TSHRL3MBTL1 | |
| SCHEMBL31442676 | 0.87 | GPR35 (0.43) | GPR35CYP1A2TDP1TSHRL3MBTL1 | |
| SCHEMBL9450226 | 0.87 | GPR35 (0.43) | GPR35CYP1A2TDP1TSHRL3MBTL1 | |
| SCHEMBL28137614 | 0.85 | FBP1 (0.54) | GPR35CYP1A2TDP1TSHRL3MBTL1 | |
| SCHEMBL1373558 | 0.83 | ALDH1A1 (0.44) | GPR35TDP1TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL1372574 | 0.82 | GPR35 (0.48) | GPR35CYP1A2TDP1TSHRALDH1A1 | |
| Acetic Acid SCHEMBL28222560 | 0.82 | TDP1 (0.44) | GPR35CYP1A2TDP1TSHRL3MBTL1 | |
| SCHEMBL6779354 | 0.82 | ALDH1A1 (0.40) | GPR35CYP1A2TDP1TSHRL3MBTL1 | |
| SCHEMBL19475267 | 0.81 | AKR1B1 (0.56) | CYP1A2TDP1TSHRAKR1B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3022182-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | BENDER DAVID MICHAEL (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030220369-A1 | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | FORMAN SCOTT LOUIS (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1313719-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1309577-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002014275-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002014294-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | GPR35 2799/4885CYP1A2 402/4885TDP1 4192/4885 |
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | GRIN2A, GRIN2B, GRIN1 | GPR35 138/4885CYP1A2 1069/4885TDP1 3131/4885 |
| US-20030220369-A1 | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | GRIN2A, GRIN1, GRIN2B | GPR35 94/4885CYP1A2 1336/4885TDP1 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.